Navigation Links
3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
Date:8/24/2010

s-releases/health-latest-news/medical-pharmaceuticals-list">Medical Pharmaceuticals, Pharmaceuticals, Contracts Click to view news release full screen  

3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China

 

SHENYANG, China, Aug. 24 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA), a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

Under the terms of the agreement, Isotechnika will grant 3SBio exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, excluding ophthalmic indications and medical devices which were previously licensed to Lux Biosciences, Inc. and Atrium Medical Corporation, respectively. 3SBio will be responsible for the clinical development, registration and commercialization of voclosporin in China. Isotechnika will provide, under separate agreement, commercial supply to 3SBio on a cost-plus basis. Isotechnika will rece
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 3SBio Inc. Announces Results of Annual General Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
(Date:10/17/2014)... UBM Medica US announces that Neurology ... information resource for neurologists and other healthcare providers, features special ... , with discussions of the latest developments in approaches to ... Parkinson disease , more than the total of those who ... disease. Diagnosis can be difficult because there are no confirmatory ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... Md., May 9, 2011 /PRNewswire-USNewswire/ – CoMeD – On ... State Senator filed an amendment to regulate vaccines containing ... illegal to buy, sell, manufacture, deliver, import, administer or ... of organic or inorganic mercury per milliliter for children ...
... BUFFALO, N.Y., May 9, 2011 Kinex Pharmaceuticals, LLC announced ... Chief Executive Officer, has decided to step aside as CEO. ... see Kinex Pharmaceuticals evolve from a start-up biotechnology company with ... of two compounds in pre-IND to phase 2 developments. The ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 3
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... 48, as Senior,Vice President and Chief Financial Officer. ... 20 years of executive,pharmaceutical experience in finance, operations, ... Chief Financial Officer for Watson,Mr. Durand will be ...
... of families with deployed Service members ... ... to the Oregon National Guard,s Emergency Relief fund, which,will support the needs of ... "TriWest made the contribution with the hope that we can make a,difference in ...
... Use of ABILIFY in Patients Ages 10 to 17 ... ... PRINCETON, N.J., Nov. 15 ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company ... for filing and granted a Priority Review to the supplemental New,Drug Application ...
... alternative for patients with erosive gastroesophageal reflux disease ... (GERD) who cannot swallow ... of Wyeth (NYSE: WYE ), announced today that the,U.S. ... Delayed-Release Oral Suspension, a new addition,to the Protonix family of ...
... Memphis PGA Tour Stop ... Jude, MEMPHIS, Tenn., Nov. 15 Stanford Financial Group CFO,James ... joined Tony,Thomas from St. Jude and Laurie Tucker, Senior Vice President ... from the,inaugural Stanford St. Jude Championship. The donation from the 2007 ...
Cached Medicine News:Health News:Low standards of child well-being linked to greater income inequality 2Health News:Watson Names Mark Durand Chief Financial Officer 2Health News:TriWest Contributes $30,000 to Oregon National Guard Fund 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 2Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: